Cited time in webofscience Cited time in scopus

Identification of Novel Autoantibodies in Type 1 Diabetic Patients Using a High-Density Protein Microarray

Identification of Novel Autoantibodies in Type 1 Diabetic Patients Using a High-Density Protein Microarray
Koo, BK[Koo, Bo Kyung]Chae, S[Chae, Sehyun]Kim, KM[Kim, Kristine M.]Kang, MJ[Kang, Min Jueng]Kim, EG[Kim, Eunhee G.]Kwak, SH[Kwak, Soo Heon]Jung, HS[Jung, Hye Seung]Cho, YM[Cho, Young Min]Choi, SH[Choi, Sung Hee]Park, YJ[Park, Young Joo]Shin, CH[Shin, Choong Ho]Jang, HC[Jang, Hak C.]Shin, CS[Shin, Chan Soo]Hwang, D[Hwang, Daehee]Yi, EC[Yi, Eugene C.]Park, KS[Park, Kyong Soo]
DGIST Authors
Hwang, D[Hwang, Daehee]
Issued Date
Article Type
AdultAgedAntibody TiterAutoantibodiesAutoantibodyBlood SamplingChildChild, PreschoolControlled StudyDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2eef1a1 AutoantibodyEnzyme Linked Immunosorbent AssayFemaleGlucose ToleranceGlutamate DecarboxylaseGraves DiseaseHumanHumansImmunoprecipitationInsulin Dependent Diabetes MellitusMajor Clinical StudyMaleMiddle AgedNon-Insulin Dependent Diabetes MellitusPeptide Elongation Factor 1PrevalencePriority JournalProtein AnalysisProtein Array AnalysisProtein MicroarrayUBE2L3 AutoantibodyUbiquitin-Conjugating EnzymesUnclassified Drug
Autoantibodies can facilitate diagnostic and therapeutic means for type 1 diabetes (T1DM). We profiled autoantibodies from serum samples of 16 T1DM patients, 16 type 2 diabetic (T2DM) patients, and 27 healthy control subjects with normal glucose tolerance (NGT) by using protein microarrays containing 9,480 proteins. Two novel autoantibodies, anti-EEF1A1 and anti-UBE2L3, were selected from microarrays followed by immunofluorescence staining of pancreas. We then tested the validity of the candidates by ELISA in two independent test cohorts: 1) 95 adults with T1DM, 49 with T2DM, 11 with latent autoimmune diabetes in adults (LADA), 20 with Graves disease, and 66 with NGT and 2) 33 children with T1DM and 34 healthy children. Concentrations of these autoantibodies were significantly higher in T1DM patients than in NGT and T2DM subjects (P < 0.01), which was also confirmed in the test cohort of children (P < 0.05). Prevalence of anti-EEF1A1 and anti-UBE2L3 antibodies was 29.5% and 35.8% in T1DM, respectively. Of note, 40.9% of T1DM patients who lack anti-GAD antibodies (GADA) had anti-EEF1A1 and/or anti-UBE2L3 antibodies. These were also detected in patients with fulminant T1DM but not LADA. Our approach identified autoantibodies that can provide a new dimension of information indicative of T1DM independent of GADA and new insights into diagnosis and classification of T1DM. © 2014 by the American Diabetes Association.
American Diabetes Association Inc.
Files in This Item:

There are no files associated with this item.

Appears in Collections:
Department of New Biology Systems Biology and Medicine Lab 1. Journal Articles


  • twitter
  • facebook
  • mendeley

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.